Research reveals that M6PR/IGF2R double-knockout provides potential therapeutic sources for mucolipidosis II and Niemann-Pick C2. This discovery could pave the way for new treatment strategies for these rare diseases.

The collaboration will test Apertura’s proprietary TfR1 CapX AAV capsid, a next-generation delivery technology designed to bind transferrin receptor 1 (TfR1) Apertura Gene Therapy is joining forces with two leading US research institutes to advance a potential new treatment approach for Niemann-Pick Disease Type C1 (NPC1), a rare and fatal genetic disorder that causes progressive neurological decline. NPC1 is a devastating autosomal recessive lysosomal storage disorder caused by mutations in the NPC1 gene. The disease leads to the buildup of cholesterol and lipids in cells, triggering severe neurological damage that can begin in early childhood. Patients often experience progressive cerebellar ataxia, dementia, and, in many cases, death during adolescence. "Systemic delivery of AAV gene therapies by intravenous administration has significant advantages over other methods of administration due to lower complexity and risks," said Forbes D. Andrew Steinsapir, Acting Chief Technology Officer of Apertura Gene Therapy and Gene Therapy Program Lead at Deerfield Management, said: "Apertura is excited to collaborate with NICHD and NHGRI and explore how an investigational gene therapy that uses TfR1 CapX can be delivered intravenously with the goal of treating Niemann-Pick Disease Type C1." "We are thrilled about this partnership. With multiple therapies now approved for NPC disease, our focus is on advancing the next generation of treatments, and we believe gene therapy holds tremendous promise," said Sean Kassen, Director of the Ara Parseghian Medical Research Fund.

Researchers have identified serum protein biomarkers in individuals with Niemann-Pick disease, type C1, which could aid in diagnosis and monitoring of the disease. This discovery enhances understanding of the disease's pathology and potential therapeutic targets.

FDA initiates real-time monitoring of cancer drug trials by AstraZeneca and Amgen to enhance efficiency in drug development. AstraZeneca's Phase 2 trial targets aggressive lymphoma, while Amgen's Phase 1b trial focuses on small cell lung carcinoma.